Wanting pharma companies to consider
quality-by-design (QbD) elements
throughout a product’s entire lifecycle,
including post-approval changes, through
integration of risk- and knowledge-based
approaches, seems to have become a
global regulatory expectation. For biologics,
however, using these approaches is
more complex and companies cannot
simply adopt the same strategies used for
traditional small molecules.